Fly News Breaks for April 27, 2015
GSK, AGEN
Apr 27, 2015 | 08:46 EDT
After Agenus' (AGEN) partner, GlaxoSmithKline (GSK), published positive, final Phase III trial results for the RTS,S/AS01 malaria vaccine, JMP Securities says the data was positive and validate the QS-21 adjuvant system. The firm reiterates an Outperform rating on Agenus.
News For AGEN;GSK From the Last 2 Days
AGEN
Mar 18, 2024 | 08:52 EDT
B. Riley analyst Mayank Mamtani lowered the firm's price target on Agenus to $5 from $6 and keeps a Buy rating on the shares. The company's Q4 earnings focused on the roadmap to BOT/BAL U.S. and EU accelerated approval submission, with management reiterating their bullish view on BOT/BAL in terms of efficacy, safety, and commercial opportunity, the analyst tells investors in a research note.